 |
Top 10 Cystic fibrosis treatment startups in USA
Oct 10, 2024 | By Jason Kwon | 19 |
1
Funding: $510.5M
Morphic Therapeutic is developing oral, small-molecule formulations aimed at the family of common cell-surface receptors linked to inflammation, fibrosis, oncology and cardiometabolic disease.
Morphic Therapeutic is developing oral, small-molecule formulations aimed at the family of common cell-surface receptors linked to inflammation, fibrosis, oncology and cardiometabolic disease.
2
Funding: $442.6M
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
3
Funding: $292M
Sionna’s batch of small molecules will be the first to fully restore function to the cystic fibrosis transmembrane conductance regulator (CFTR) protein
Sionna’s batch of small molecules will be the first to fully restore function to the cystic fibrosis transmembrane conductance regulator (CFTR) protein
4
Funding: $145.6M
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
5
Funding: $63M
Stablix Therapeutics, a biotechnology company pioneering the Targeted Protein Stabilization technologies that is used to cure cystic fibrosis and cancer
Stablix Therapeutics, a biotechnology company pioneering the Targeted Protein Stabilization technologies that is used to cure cystic fibrosis and cancer
6
Funding: $60M
Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology. Our approach opens new avenues for the treatment of cancer, fibrosis, ischemia, and immune modulation.
Kojin Therapeutics is developing transformative medicines based on a groundbreaking approach to ferroptosis and cell state biology. Our approach opens new avenues for the treatment of cancer, fibrosis, ischemia, and immune modulation.
7
Funding: $53.9M
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions. Our therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. We aim to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions.
8
Funding: $38M
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
9
Funding: $34M
Trucode develops gene editing assets designed to correct the mutations behind diseases including sickle cell and cystic fibrosis.
Trucode develops gene editing assets designed to correct the mutations behind diseases including sickle cell and cystic fibrosis.
10
Funding: $1.8M
Deton is transforming the understanding and treatment of lung disease by providing complete and timely lung health information thru Aerosol Biopsy
Deton is transforming the understanding and treatment of lung disease by providing complete and timely lung health information thru Aerosol Biopsy
